LUNGevity research is 100% patient-focused. We conduct and fund research that has potential to revolutionize outcomes for those diagnosed with lung cancer.
With our strategic approach to translational research in two priority areas—finding lung cancer early and treating it more effectively—our research speeds breakthroughs to patients so people can live longer and better lives.
LUNGevity builds on the success of these research programs by partnering and collaborating with other organizations to make the greatest progress in advancing science for patients. LUNGevity collaborates with organizations like Stand Up To Cancer and American Lung Association to fund large, multi-institution early detection projects.
LUNGevity ensures research is impactful by partnering with patient groups like ALK Positive, a group of 1,000+ ALK-positive patients and their caregivers in 41 countries who are raising significant funds for research into their specific biomarker.
LUNGevity’s Patient-Focused Research Center (Patient FoRCe) is changing the paradigm in lung cancer from assumptions being made about patient preferences to evidence-based conclusions about what patients value.
LUNGevity is researching new ways to reduce health disparities in lung cancer through our Community-Based Participatory Research program, which brings together researchers and community stakeholders as equal partners in the research process.